{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LUM001",
    "query": {
      "intervention": "LUM001"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LUM001&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T15:15:04.571Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03905330",
      "title": "A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Progressive Familial Intrahepatic Cholestasis (PFIC)"
      ],
      "interventions": [
        {
          "name": "Maralixibat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 93,
      "start_date": "2019-07-09",
      "completion_date": "2022-09-01",
      "has_results": true,
      "last_update_posted_date": "2023-12-11",
      "last_synced_at": "2026-09-04T15:15:04.571Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03905330"
    },
    {
      "nct_id": "NCT02475317",
      "title": "Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Maralixibat",
          "type": "DRUG"
        },
        {
          "name": "Volixibat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 84,
      "start_date": "2015-06-01",
      "completion_date": "2015-12-01",
      "has_results": false,
      "last_update_posted_date": "2019-04-04",
      "last_synced_at": "2026-09-04T15:15:04.571Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02475317"
    },
    {
      "nct_id": "NCT02061540",
      "title": "Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis (PSC)"
      ],
      "interventions": [
        {
          "name": "LUM001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 27,
      "start_date": "2014-03",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2019-03-29",
      "last_synced_at": "2026-09-04T15:15:04.571Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Sacramento, California • Aurora, Colorado + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02061540"
    },
    {
      "nct_id": "NCT02057718",
      "title": "Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Progressive Familial Intrahepatic Cholestasis (PFIC)"
      ],
      "interventions": [
        {
          "name": "LUM001 (Maralixibat)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Months to 18 Years"
      },
      "enrollment_count": 33,
      "start_date": "2014-03-01",
      "completion_date": "2020-05-08",
      "has_results": true,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-09-04T15:15:04.571Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057718"
    },
    {
      "nct_id": "NCT02057692",
      "title": "Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alagille Syndrome"
      ],
      "interventions": [
        {
          "name": "LUM001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Months to 18 Years"
      },
      "enrollment_count": 37,
      "start_date": "2014-11-24",
      "completion_date": "2016-11-16",
      "has_results": true,
      "last_update_posted_date": "2019-03-26",
      "last_synced_at": "2026-09-04T15:15:04.571Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057692"
    },
    {
      "nct_id": "NCT06553768",
      "title": "Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)"
      ],
      "interventions": [
        {
          "name": "Maralixibat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 90,
      "start_date": "2024-10-14",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-04T15:15:04.571Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06553768"
    },
    {
      "nct_id": "NCT02117713",
      "title": "An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alagille Syndrome"
      ],
      "interventions": [
        {
          "name": "LUM001 (Maralixibat)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 34,
      "start_date": "2015-03-16",
      "completion_date": "2020-06-01",
      "has_results": true,
      "last_update_posted_date": "2021-07-01",
      "last_synced_at": "2026-09-04T15:15:04.571Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02117713"
    },
    {
      "nct_id": "NCT04729751",
      "title": "A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Progressive Familial Intrahepatic Cholestasis",
        "Alagille Syndrome",
        "Cholestatic Liver Disease"
      ],
      "interventions": [
        {
          "name": "Maralixibat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "364 Days",
        "sex": "ALL",
        "summary": "0 Days to 364 Days"
      },
      "enrollment_count": 27,
      "start_date": "2021-09-09",
      "completion_date": "2024-12-17",
      "has_results": true,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-09-04T15:15:04.571Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04729751"
    },
    {
      "nct_id": "NCT02321306",
      "title": "An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cirrhosis"
      ],
      "interventions": [
        {
          "name": "LUM001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-05",
      "completion_date": "2018-03",
      "has_results": false,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-09-04T15:15:04.571Z",
      "location_count": 13,
      "location_summary": "La Jolla, California • Sacramento, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02321306"
    },
    {
      "nct_id": "NCT04524390",
      "title": "Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Biliary Atresia"
      ],
      "interventions": [
        {
          "name": "Maralixibat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Days",
        "maximum_age": "111 Days",
        "sex": "ALL",
        "summary": "21 Days to 111 Days"
      },
      "enrollment_count": 75,
      "start_date": "2021-07-08",
      "completion_date": "2024-02-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-09-04T15:15:04.571Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Atlanta, Georgia • New York, New York + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04524390"
    }
  ]
}